TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20875370

Group type: EXPERIMENTAL
Intervention: Ticagrelor 900 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 18172233

Group type: EXPERIMENTAL
Intervention: Using magnification loupes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Using magnification loupes immediately on entering the program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not using magnification loupes
Number of subjects: 35
Study: 15690268

Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg mixed with hyperbaric ropivacaine 10 mg (group FR10)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 15 mg (group R15)
Number of subjects: 60
Study: 12753258

Group type: EXPERIMENTAL
Intervention: COLIA1 polymorphism (specifically the 'ss' genotype)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Utilization of haplotypes of VDR gene polymorphisms
Number of subjects: 156

Group type: COMPARATOR
Intervention: VDR gene polymorphisms
Number of subjects: 156
Study: 10569649

Group type: EXPERIMENTAL
Intervention: TNK-tPA 30 mg
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: TNK-tPA 40 mg
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: TNK-tPA 50 mg
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Mid-dose tertile (0.40 to 0.51 mg/kg)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: High-dose tertile (0.52 to 1.24 mg/kg)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Low-dose tertile (0.2 to 0.39 mg/kg)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: High-dose and mid-dose tertiles
Number of subjects: 886
Study: 8947402

Group type: EXPERIMENTAL
Intervention: Power squat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Front squat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lunge
Number of subjects: 0
Study: 1844195

Group type: EXPERIMENTAL
Intervention: Biological monitoring (cervical mucus) for HCG administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biochemical monitoring for HCG administration
Number of subjects: 0
Study: 6996111

Group type: EXPERIMENTAL
Intervention: Folic acid supplement (15 mg folic acid per day for 5 weeks)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31826931

Group type: EXPERIMENTAL
Intervention: BRAF inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of BRAF inhibition and TP53 reactivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue-specific mutation–drug associations
Number of subjects: 0
Study: 31188881

Group type: EXPERIMENTAL
Intervention: Axiological-Identitary Collective Action Model (AICAM)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Alternative models (including SIMCA)
Number of subjects: 1138
Study: 28975664

Group type: EXPERIMENTAL
Intervention: Torasemide q24h (median dose = 0.24 mg/kg/d; range = 0.10–0.69 mg/kg/d)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 366

Group type: COMPARATOR
Intervention: Furosemide q12h (median dose = 1.39 mg/kg q12h; range = 0.70–6.30 mg/kg q12h)
Number of subjects: 366
Study: 26695795

Group type: EXPERIMENTAL
Intervention: Drug treatment for type A SSNHL (acute in low tone frequencies) with FEF
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Drug treatment for type B SSNHL (acute in high tone frequencies) with FEF
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Drug treatment for type C SSNHL (acute in all frequencies) with FEF
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Drug treatment for type D SSNHL (total deafness) with FEF
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Drug treatment for type A SSNHL without FEF
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Drug treatment for type B SSNHL without FEF
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Drug treatment for type C SSNHL without FEF
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Drug treatment for type D SSNHL without FEF
Number of subjects: 1024
Study: 23995661

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: In vitro disintegration time measured using Tricorptester
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation between in vitro and clinical disintegration times
Number of subjects: 10
Study: 21411411

Group type: EXPERIMENTAL
Intervention: 1% Glechoma hederacea extract lotion applied topically for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19153829

Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (L + C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 0
Study: 16454975

Group type: EXPERIMENTAL
Intervention: XS0601
Number of subjects: 335
Study: 15181129

Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 collaterals (Group I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Grade 3 collaterals (Group II)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 56
Study: 11402116

Group type: EXPERIMENTAL
Intervention: Local methylprednisolone injection (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisolone (low-dose, short-term)
Number of subjects: 0
Study: 9248031

Group type: EXPERIMENTAL
Intervention: Full-facepiece masks with clouded lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pre-exercise visual acuity
Number of subjects: 10
Study: 8392263

Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of fetal biparietal diameter (BPD)
Number of subjects: 1713

Group type: COMPARATOR
Intervention: Last menstrual period (LMP)
Number of subjects: 1713

Group type: EXPERIMENTAL
Intervention: Comparison of EDDs calculated from BPD and LMP
Number of subjects: 1713
Study: 3525866

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (1 mg. 3 times daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Estramustine phosphate (280 mg. twice daily for 8 weeks and 140 mg. twice daily thereafter)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Estramustine phosphate
Number of subjects: 227
Study: 30304120

Group type: EXPERIMENTAL
Intervention: One implant (GI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Two implants (GII)
Number of subjects: 21
Study: 27014909

Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin with radiotherapy (Capox‐RT group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine with radiotherapy (Cap‐RT group)
Number of subjects: 0
Study: 24368436

Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 376

Group type: COMPARATOR
Intervention: No LNS (Control)
Number of subjects: 376
Study: 22311634

Group type: EXPERIMENTAL
Intervention: ChitoHem(®) powder
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional hemostatic procedure
Number of subjects: 124
Study: 20371746

Group type: COMPARATOR
Intervention: <200 kcal/week of leisure-time physical activity
Number of subjects: 39315

Group type: EXPERIMENTAL
Intervention: 200 to 599 kcal/week of leisure-time physical activity
Number of subjects: 39315

Group type: EXPERIMENTAL
Intervention: 600 to 1499 kcal/week of leisure-time physical activity
Number of subjects: 39315

Group type: EXPERIMENTAL
Intervention: > or =1500 kcal/week of leisure-time physical activity
Number of subjects: 39315

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 39315

Group type: EXPERIMENTAL
Intervention: Walking time and walking pace
Number of subjects: 39315
Study: 16648508

Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg every 2 hours as needed, maximum of four capsules a day for 7 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (every 2 hours as needed, maximum of four capsules a day for 7 days)
Number of subjects: 112
Study: 16249975

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day, p.o.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day, p.o. + famotidine 40 mg/day, p.o.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rabeprazole treatment (before treatment)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Combination therapy (before treatment)
Number of subjects: 10
Study: 11729332

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) every-other-day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study: 9145087

Group type: EXPERIMENTAL
Intervention: Nutrient and food intakes of infants
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Fat intake
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Reduced-fat milks consumption
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Variety of foods consumed
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Calcium intake from dairy products
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Nutritional issues identified
Number of subjects: 94
Study: 8130395

Group type: EXPERIMENTAL
Intervention: Transverse process fusion with autogenous iliac crest bone graft and instrumentation (Group III)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No fusion (Group I)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Transverse process fusion without instrumentation (Group II)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Spondylolisthesis unchanged subjects
Number of subjects: 43
Study: 3119340

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 27966192

Group type: EXPERIMENTAL
Intervention: SDM intervention (12-h SDM training program for physicians in combination with decision board use)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients treated by SDM-trained physicians
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SDM intervention
Number of subjects: 107
Study: 27595402

Group type: EXPERIMENTAL
Intervention: Transperineal prostatic block (TPPB) with 10 ml 2% prilocaine (Group-I)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Intrarectal lidocaine gel (10 ml 2% lidocaine) followed by periprostatic nerve blockage (PPNB) with 10 ml 2% prilocaine (Group-II)
Number of subjects: 376
Study: 23877377

Group type: EXPERIMENTAL
Intervention: EX60 (60 min of moderate treadmill exercise at 56% peak V˙O2)
Number of subjects: 18
Study: 22068425

Group type: EXPERIMENTAL
Intervention: AAV2.5 vector injected into the bicep muscle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control injected into the contralateral arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AAV empty capsid
Number of subjects: 0
Study: 20466473

Group type: EXPERIMENTAL
Intervention: Alveolar distraction osteogenesis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sandwich osteotomy technique and tibial bone grafting
Number of subjects: 12
Study: 18689371

Group type: EXPERIMENTAL
Intervention: Daily 500 mcg phylloquinone supplementation for 3 years
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (no phylloquinone supplementation)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation
Number of subjects: 379
Study: 15711432

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 31
Study: 15331394

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) + oral placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Diacerein 100 mg/day + IA injections of saline solution
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Oral placebo + IA injections of saline solution
Number of subjects: 301
Study: 11425926

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 22 mcg tiw
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a, 44 mcg tiw
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 9402534

Group type: EXPERIMENTAL
Intervention: Sarin cases (exposed to sarin)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 18
Study: 8352372

Group type: EXPERIMENTAL
Intervention: 5-ASA enemas
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 14
Study: 2441162

Group type: EXPERIMENTAL
Intervention: 1 mg S-9780
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 mg S-9780
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4 mg S-9780
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31750699

Group type: EXPERIMENTAL
Intervention: Mindfulness-based yogic breathing (MB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive strategy (CS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment (NT)
Number of subjects: 60
Study: 29030287

Group type: EXPERIMENTAL
Intervention: Heterotopic noxious counter-stimulation (HNCS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Selective attention
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Heterotopic noxious counter-stimulation (HNCS) with attention directed toward the HNCS stimulus
Number of subjects: 17
Study: 28484897

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation at 50 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation at 100 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation at 300 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation at 500 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation at 56.3 mg/kg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation (incremental levels)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dietary vitamin E supplementation from 56.3 to 588.4 mg/kg
Number of subjects: 3
Study: 26559363

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for depression group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for schizophrenia group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 24474233

Group type: EXPERIMENTAL
Intervention: Mesalazine (Pentasa®) 2 g sachet once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesalazine (twice daily in tablets)
Number of subjects: 0
Study: 21199957

Group type: EXPERIMENTAL
Intervention: Bupropion treatment for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 30
Study: 18457235

Group type: EXPERIMENTAL
Intervention: Persistent Insomnia
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Usual care for depression
Number of subjects: 1801

Group type: COMPARATOR
Intervention: Enhanced care for depression
Number of subjects: 1801

Group type: COMPARATOR
Intervention: No Insomnia
Number of subjects: 1801

Group type: EXPERIMENTAL
Intervention: Intermediate Insomnia
Number of subjects: 1801
Study: 16551141

Group type: EXPERIMENTAL
Intervention: Intervention (n=80): 12-week parenting course (Incredible Years) and co-parenting component
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (n=48): Usual care
Number of subjects: 128
Study: 14560767

Group type: EXPERIMENTAL
Intervention: Spectral analysis
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Scaling analysis
Number of subjects: 78
Study: 10919933

Group type: EXPERIMENTAL
Intervention: High-isoflavone dietary treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Low-isoflavone dietary treatment
Number of subjects: 24
Study: 8960603

Group type: EXPERIMENTAL
Intervention: Echocardiographic automated boundary detection (ABD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional manual echocardiographic methods
Number of subjects: 0
Study: 1404628

Group type: EXPERIMENTAL
Intervention: Intussuscepted nipple valve
Number of subjects: 40

Group type: COMPARATOR
Intervention: Le Duc mucosal trough technique
Number of subjects: 40
Study: 3905342

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 40
Study: 31922372

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (high frequency 100 Hz, medium frequency 50 or 60 Hz, low frequency 25 Hz)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (high frequency over vertex)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cognitive measures
Number of subjects: 26
Study: 31741561

Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthesia with 2% lidocaine and epinephrine 1/100000 (LA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.25% levobupivacaine (LB)
Number of subjects: 60
Study: 28095051

Group type: EXPERIMENTAL
Intervention: Group intervention and workbook
Number of subjects: 12

Group type: COMPARATOR
Intervention: Workbook only (Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (Treatment and Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 12
Study: 25873530

Group type: EXPERIMENTAL
Intervention: Weight management group (dietary and exercise program)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (health education)
Number of subjects: 120
Study: 23703424

Group type: EXPERIMENTAL
Intervention: Painful pressure stimulus of 1,500 kPa applied to the middle phalanx of the right middle finger
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Moderate to severe anxiety
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gender comparison (Men vs Women)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gender and anxiety level
Number of subjects: 96
Study: 21144659

Group type: EXPERIMENTAL
Intervention: Low-frequency TENS (4Hz)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100Hz)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DNIC (Diffuse noxious inhibitory control)
Number of subjects: 100
Study: 19481687

Group type: EXPERIMENTAL
Intervention: Testopatch applied on thigh
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testopatch applied on upper arm
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testopatch at 2.0 h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testopatch at lower back
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Testopatch
Number of subjects: 24
Study: 16473376

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 842

Group type: COMPARATOR
Intervention: Non-participants (non-volunteers)
Number of subjects: 842
Study: 15109188

Group type: EXPERIMENTAL
Intervention: Vital capacity rapid inhalation induction at 8% sevoflurane (Group VC8)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Vital capacity rapid inhalation induction at 4.5% sevoflurane (Group VC4.5)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional stepwise inhalation induction (Group C)
Number of subjects: 125
Study: 11687365

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical plus intracameral anesthesia
Number of subjects: 75

Group type: COMPARATOR
Intervention: No anesthesia
Number of subjects: 75
Study: 9174114

Group type: EXPERIMENTAL
Intervention: LY293111 48 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LY293111 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LY293111
Number of subjects: 20
Study: 7697690

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/d for 4 weeks
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/d for 4 weeks
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/d for 6 months
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every other day for 6 months
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Omeprazole (both doses)
Number of subjects: 156
Study: 3310639

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (800 mg elemental calcium per day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcium citrate (800 mg elemental calcium per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 26
Study: 31102684

Group type: EXPERIMENTAL
Intervention: High-Intensity Circuit Training (HICT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 33
Study: 28603176

Group type: EXPERIMENTAL
Intervention: BM-MNC implantation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: BM-MNC treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Secondary endpoints (pain, ulcers, TcPO2, ankle-brachial index)
Number of subjects: 38
Study: 24176229

Group type: EXPERIMENTAL
Intervention: 500 mg choline daily for 9 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21644310

Group type: EXPERIMENTAL
Intervention: Ginger-partition moxibustion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Suspended moxibustion
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ginger-partition moxibustion at Shengshu (BL 23)
Number of subjects: 43
Study: 18077211

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nCPAP) treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (subjects without OSA and with mild OSA)
Number of subjects: 46
Study: 16963674

Group type: EXPERIMENTAL
Intervention: Therapeutic nCPAP (optimal pressure, n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham nCPAP (suboptimal pressure of 1 to 2 cm H2O, n = 10)
Number of subjects: 25
Study: 15309692

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Arrhythmia group
Number of subjects: 949

Group type: COMPARATOR
Intervention: No arrhythmia group
Number of subjects: 949
Study: 12915605

Group type: EXPERIMENTAL
Intervention: Consolidation workshops (6 sessions of 3 hours each after basic training)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 63